| Field | Specification |
|---|---|
| Target | |
| Alternative names | GSK'843 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C19H15N5S2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
GSK-843, also known as GSK'843, inhibits receptor-interacting protein kinase 3 (RIP3 or RIPK3), binding the RIP3 kinase domain with an IC50 of 8.6 nM and inhibiting kinase activity with an IC50 of 6.5 nM. It can be used for inflammation research[1][2]. It is supplied as a light yellow to yellow solid (C19H15N5S2, MW 377.49) at 99.53% purity.
Physical & Chemical Properties
| CAS Number | 1601496-05-2 |
|---|---|
| Molecular Formula | C19H15N5S2 |
| Molecular Weight | 377.49 g/mol |
| Purity | 99.53% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | NC1=NC=C(C2=CC(C)=NN2C)C3=C1C(C4=CC=C(SC=N5)C5=C4)=CS3 |
| Target | RIPK3 |
| Signaling Pathway | Apoptosis |
| Solubility | In Vitro: DMSO: 50 mg/mL (132.45 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years. In solvent: -80°C, 1 year; -20°C, 6 months. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (132.45 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 4.8 mg/mL (12.72 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 4.8 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (48.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 2
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.51 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vitro
Apoptosis is induced by GSK-843 (3-10 μM; 18 h)[1]. At 0.3-3 μM for 18 h, GSK-843 suppresses TNF-induced death and virus-induced cell necrosis[2].
Cell Viability Assay[1]
| Cell Line | SVEC, L929, 3T3SA and mouse embryo fibroblast (MEF) |
|---|---|
| Concentration | 3 and 10 μM |
| Incubation Time | 18 hours |
| Result | Decreased the cell viability of SVEC, L929, 3T3SA and MEF cells, and induced caspase activation followed by apoptotic cell death. |
Cell Viability Assay[2]
| Cell Line | 3T3-SA and SVEC4-10 cells |
|---|---|
| Concentration | 0.3, 1 and 3 μM |
| Incubation Time | 18 hours |
| Result | Dose-dependently suppressed TNF-induced death and virus-induced necrosis to improved cell viability. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Structure-based design of potent and selective inhibitors targeting RIPK3 for eliminating on-target toxicity in vitro. Nat Commun 2025 May 8;16(1):4288. PMID: 40341069
Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control. Sci Adv 2025 Aug 15;11(33):eadv0871. PMID: 40815638
cFLIP suppresses caspase-1- and MLKL-independent perinatal lethality driven by auto-processing impaired caspase-8 D387A. Cell Death Differ 2025 Dec 12. PMID: 41381861
Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion. Cancer Lett 2023 Jun 28:564:216208. PMID: 37150500
Loss of Ripk3 attenuated neutrophil accumulation in a lipopolysaccharide-induced zebrafish inflammatory model. Cell Death Discov 2022 Feb 26;8(1):88. PMID: 35220408
Autoinhibitory control of MLKL governs pseudokinase domain phosphorylation and oligomerization during necroptosis. Cell Rep 2026 Mar 20;45(4):117130. PMID: 41863805
Enhanced RIPK3 kinase activity-dependent lytic cell death in M1 but not M2 macrophages. Mol Immunol 2021 Jan:129:86-93. PMID: 33221042
University of Cologne. 2024.
